Regeneron rockets as financial results provide perfect picture of growth

5 May 2020

Investors in Regeneron Pharmaceuticals (Nasdaq: REGN) could afford a rare smile in these difficult times, as the company’s first quarter 2020 results came in on Tuesday, sending shares 7% higher by midday.

First quarter revenues at the US biotech – a frequent partner of French drugmaker Sanofi (Euronext: SAN) – rose by 33% to $1.83 billion, while diluted earnings per share hit $6.60, ahead of analyst expectations of $6.09.

As well as boasting impressive sales of its Sanofi-partnered blockbuster Dupixent (dupilumab), and Bayer (BAYN: DE) partnered Eylea (aflibercept), as well as Regeneron’s newer assets look good, with Libtayo (cemiplimab-rwlc), licensed to Sanofi, showing clinically-meaningful and durable responses in pivotal second-line advanced basal cell carcinoma trial ahead of likely regulatory submissions later this year. The company’s COVID-19 efforts also include a SARS-CoV-2 antibody cocktail treatment that is moving forward rapidly.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK